In case you’re on the fence about taking Taltz, here is some case study statistics for you to read. Taltz has no black box warnings. They also approved the drug for children over six years of age. I was on Taltz and I found it extremely effective. At the time it was painful to inject. They now make it without the citrate as a preservative, so the medication is painless to take. Overall I rate this drug a 9 out of 10 only because I got 4 years of use rather than 5. The content below is cited by NCBI.
“Ixekizumab is a high-affinity, humanized IgG4 monoclonal antibody for IL-17A, inhibiting interaction with the IL-17 receptor. FDA indications for ixekizumab include plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. The loading dose is 160 mg SC at week 0 and subsequent doses of 80 mg at weeks 2, 4, 6, 8, 10, and 12. Maintenance dosing is continued at 80 mg SC every 4 weeks. To maintain response to treatment, practitioners can consider increasing the dosing regimen to 80 mg SC every 2 weeks. It is the only biologic with data and FDA labeling specifically for genital plaque psoriasis. Also, ixekizumab is the only IL-17 agent that is FDA approved for treatment of plaque psoriasis down to the age of 6 years old. Ixekizumab was shown to be superior to placebo in the treatment of moderate‐to‐severe pediatric psoriasis, and the safety profile was generally consistent with that observed in adults.
Ixekizumab has very high efficacy as demonstrated through a PASI 75 achievement in 90% of patients by week 12. Efficacy data points to ixekizumab as being the fastest acting biologic. Head-to-head comparison showed a faster onset of action than guselkumab in the treatment of plaque psoriasis In head-to-head studies against adalimumab for treatment of psoriatic arthritis, both biologics were found to have similar symptom control and inhibition of joint destruction and bone erosion. Additionally, when both PASI 100 rates and psoriatic arthritis improvement results were combined, ixekizumab was superior to adalimumab.
Head-to-head comparison showed faster onset of action for ixekizumab vs guselkumab in the treatment of plaque psoriasis. The red box indicates the primary endpoint for the study. Notes:Reproduced from Blauvelt et. al. Ixekizumab vs. Guselkuamb: …
Ixekizumab is a well-tolerated biologic with minimal adverse events. It has no black box safety warnings and no evidence of increased tuberculosis risk. Of note, there is a higher rate of injection site pain and reaction, but during phase III studies 97% of patients with a reaction did not find it significant enough to discontinue the study. Injection site reaction was actually noted to improve over the course of treatment. There is also a concern of increased risk of IBD, however, the incidence of new-onset IBD is less than 1 out of 1000 patients on ixekizumab. Studies showed a slight increase in superficial fungal and yeast infections, although the candida rate in phase III studies is still less than 0.6% while on the once every 4 weeks dosing regimen versus 0.5% on placebo.”